Navigation Links
Scientist Warns Industry Not to Ignore Potential Health Threat to Pharmacy Workers

- Recently issued study that found retail pharmacy workers are exposed to

airborne pharmaceutical agents needs further review -

DREXEL, Mo., Nov. 10 /PRNewswire/ -- AlburtyLab's President, David Alburty issued a statement today regarding serious concerns about efforts by McKesson/Parata to misrepresent and diminish the potential health threats that pharmacy workers face when they work in pharmacies using air pressure driven dispensing machines.

Statement by David Alburty:

Communications recently issued by McKesson/Parata regarding potential exposure of pharmacy workers to airborne pill dust when they use air pressure driven drug dispensing machines attempt to mask a potentially serious health matter affecting pharmacy workers.

McKesson/Parata claims that unreleased tests they performed, not conducted by Occupational Safety and Health Administration (OSHA) but "under OSHA standards (set by *1 NIOSH)," are relevant to this issue. They are not.

It is critical to know that OSHA air quality regulations are limited to general guidelines for "nuisance dust" such as emissions from grinding and burning processes. There are no OSHA standards establishing safe quantities of pharmaceutical compounds in the air. Nor are there OSHA standards for PM-2.5 particles and nanoparticles. These very small particles, which are used to transport pharmaceutical agents, have been shown to be generated when pills are subjected to air pressure dispensing.

PM-2.5 particles are the subject of EPA air quality standards and World Health Organization guidelines because they penetrate the lungs deeply and rapidly enter the bloodstream. As documented in our (AlburtyLab, October 2008) study, these particles are believed to cause a number of serious health problems. The fact that OSHA standards do not yet address this issue does not mean that it should be ignored.

Our study unveiled potentially serious exposures for pharmacy workers, and our strong recommendation is that the issue needs to be studied by federal regulatory agencies. As reported by the publication Inside OSHA on October 27, 2008, "A NIOSH official says that he believes pharmacists are being exposed to harmful particles." He further stated, "The agency advises against using technology that produces any type of particulate that could be inhaled."

The official described our study as "fairly straightforward" and said that there is concern that drugs involved were "not meant to be inhaled."

Clearly, federal regulatory agencies must assess risk and set guidelines for these types of machines and establish procedures to monitor the health impact on pharmacy workers when they are used.

The previous press release, the executive summary and the full study are available for review.

About AlburtyLab, Inc.

AlburtyLab is an independent laboratory located in Drexel, Missouri that serves the aerosol research, development, and instrumentation communities. AlburtyLab has conducted independent studies for a range of agencies and companies, including Boeing/US Navy, Boston Scientific, Northrop Grumman, US Postal Service, US Department of Homeland Security, and the US Army Research Laboratory.

Technical questions may be directed to Mr. Alburty at (816) 619-3374 or via email to

This study was funded by one of the technologies reviewed in the evaluation, ScriptPro LLC of Mission, Kansas.

The Executive Summary and the final report can be found at

*1 NIOSH (National Institute of Occupational Safety and Health) that created testing specifications required by OSHA.

Contact: Josh Fenton, The Fenton Group

Tel. 401-490-4888/401-497-0186

SOURCE AlburtyLab, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Scientists Probe Sepsis Deadly Secrets
3. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
4. Scientists Develop Natural Protection for Stored Foods
5. Scientists detect presence of marburg virus in african fruit bats
6. Scientists Spot Brains Free Will Center
7. Scientists ID Likely Culprit in Popcorn Lung
8. Scientists explain how insulin secreting cells maintain their glucose sensitivity
9. Scripps Research scientists shed new light on how antibodies fight HIV
10. Scientists, physicians present latest findings in personalized cancer treatment and prevention
11. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
Post Your Comments:
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... in the 1980s we have seen vast improvements in scientific research and discoveries, ... significant strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), ... at the Radiological Society of North America (RSNA) 2015 annual meeting through December ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic and ... to the devices for sale in the United States. Clarity is a Superior ... nm Nd:YAG lasers, into a single platform that is easy to own and operate. ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... and SACC-USA through membership and leadership since 2008. Gary Bruce, President of PartnerTech ... . Gary has spent a significant amount of time in Sweden since joining ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... --  MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), a ... an Investigational New Drug Application (IND) with the U.S. ... fully human antibody product HuMab 5B1 as a therapeutic ... the Phase I clinical trial early in 2016. ... planned Phase I trial will evaluate the safety, tolerability ...
(Date:12/1/2015)... 2015  Booth #3506 – Claymount is featuring its full ... of the Radiological Society of North America ... Based in the Netherlands , Claymount is ... (NYSE: VAR ) and is one of the world,s ... state automatic exposure control systems for controlling dose during medical ...
(Date:12/1/2015)... , Dec. 1, 2015  Lexicon Pharmaceuticals, ... that top-line data from its TELECAST Phase ... in treating carcinoid syndrome in cancer patients ... clinical benefit observed in its pivotal TELESTAR ... a companion to TELESTAR primarily to provide ...
Breaking Medicine Technology: